CAMBRIDGE, Mass., Oct. 12,
2023 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today announced that it will host a live conference
call and webcast at 8:00 a.m. ET on Thursday, October 26, 2023, to report its third
quarter financial results and provide a corporate update.
To access the live conference call, please dial 833-470-1428
(domestic) or 404-975-4839 (international), and refer to conference
ID 368229. A webcast of the call will also be available under
"Events and Presentations" in the Investors & Media section of
the Blueprint Medicines website at
http://ir.blueprintmedicines.com/. The archived webcast will be
available on Blueprint Medicines' website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities, to
rapidly and reproducibly translate our scientific innovation into a
broad pipeline of important approved and investigational precision
therapies aimed at addressing difficult-to-treat cancers and blood
disorders. Today, we are delivering our approved medicines to
patients in the United States,
Europe, and in other geographies
ourselves or through our partners. In addition, we are globally
advancing multiple programs for systemic mastocytosis, lung cancer,
breast cancer, and other genomically defined cancers, and cancer
immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on
Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-third-quarter-2023-financial-results-on-thursday-october-26-2023-301954149.html
SOURCE Blueprint Medicines Corporation